What is Alkermes Plc's earnings per share (EPS)?

Alkermes Plc (ALKS) reported diluted earnings per share of $1.43 for fiscal year 2025. This represents a -34.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Alkermes Plc Financials

ALKS

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Alkermes Plc (ALKS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ALKS FY2025 2026-05-05

Alkermes now looks like a high-gross-margin, low-capex business today where cash generation has stayed stronger than reported profit trends.

Recently, operating margin compressed from 27.0% to 17.2% as spending rose faster than sales. Yet operating cash flow climbed to $521M and free cash flow to $480M, implying the earnings slowdown was cushioned by strong cash conversion and a business that needs little reinvestment to run.

The latest pressure came below gross profit, not in product economics: gross margin improved to 86.7% while R&D plus SG&A reached about $1.03B. That pattern suggests the core revenue base remains structurally lucrative, but more of that gross profit is being consumed by operating investment rather than dropping through to operating income.

The balance sheet also looks more self-funded: liabilities were $668M against equity of $1.82B. With a current ratio of 3.5x and capex of only $40M, short-term obligations appear well covered and cash generation is not being eaten up by heavy asset replacement. That is a sturdier posture than a business that must borrow simply to maintain operations.

Financial Health Signals

Financial Profile 69/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Alkermes Plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Alkermes Plc has an operating margin of 17.2%, meaning the company retains $17 of operating profit per $100 of revenue. This strong profitability earns a score of 70/100, reflecting efficient cost management and pricing power. This is down from 27.0% the prior year.

Growth

Alkermes Plc's revenue declined 5.2% year-over-year, from $1.6B to $1.5B. This contraction results in a growth score of 24/100.

Leverage

100

Alkermes Plc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.55, Alkermes Plc holds $3.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 69/100.

Cash Flow

Alkermes Plc converts 32.6% of revenue into free cash flow ($480.3M). This strong cash generation earns a score of 96/100.

Returns

Alkermes Plc's ROE of 13.3% shows moderate profitability relative to equity, earning a score of 56/100. This is down from 25.1% the prior year.

Altman Z-Score Safe

6.72

Alkermes Plc scores 6.72, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.2B) relative to total liabilities ($667.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

Alkermes Plc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

2.15x

For every $1 of reported earnings, Alkermes Plc generates $2.15 in operating cash flow ($520.8M OCF vs $241.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

20.7x

Alkermes Plc earns $20.7 in operating income for every $1 of interest expense ($254.0M vs $12.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.5B

YoY-5.2%

5Y CAGR+7.3%

10Y CAGR+8.9%

Alkermes Plc generated $1.5B in revenue in fiscal year 2025. This represents a decrease of 5.2% from the prior year.

EBITDA

$281.1M

YoY-37.4%

Alkermes Plc's EBITDA was $281.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 37.4% from the prior year.

Net Income

$241.7M

YoY-34.2%

Alkermes Plc reported $241.7M in net income in fiscal year 2025. This represents a decrease of 34.2% from the prior year.

EPS (Diluted)

$1.43

YoY-34.1%

Alkermes Plc earned $1.43 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 34.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$480.3M

YoY+18.4%

5Y CAGR+63.9%

Alkermes Plc generated $480.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 18.4% from the prior year.

Cash & Debt

$388.6M

YoY+33.5%

5Y CAGR+7.3%

10Y CAGR+7.9%

Alkermes Plc held $388.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

166M

YoY+1.8%

5Y CAGR+0.8%

10Y CAGR+0.9%

Alkermes Plc had 166M shares outstanding in fiscal year 2025. This represents an increase of 1.8% from the prior year.

Margins & Returns

Gross Margin

86.7%

YoY+2.4pp

5Y CAGR+3.9pp

10Y CAGR+8.8pp

Alkermes Plc's gross margin was 86.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.4 percentage points from the prior year.

Operating Margin

17.2%

YoY-9.8pp

5Y CAGR+28.0pp

10Y CAGR+52.9pp

Alkermes Plc's operating margin was 17.2% in fiscal year 2025, reflecting core business profitability. This is down 9.8 percentage points from the prior year.

Net Margin

16.4%

YoY-7.2pp

5Y CAGR+27.1pp

10Y CAGR+52.5pp

Alkermes Plc's net profit margin was 16.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.2 percentage points from the prior year.

Return on Equity

13.3%

YoY-11.8pp

5Y CAGR+23.7pp

10Y CAGR+30.6pp

Alkermes Plc's ROE was 13.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 11.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$324.0M

YoY+32.1%

5Y CAGR-3.9%

10Y CAGR-0.6%

Alkermes Plc invested $324.0M in research and development in fiscal year 2025. This represents an increase of 32.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$40.4M

YoY+20.7%

5Y CAGR-0.9%

10Y CAGR-2.7%

Alkermes Plc invested $40.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 20.7% from the prior year.

ALKS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.5B-5.2%	$1.6B-6.4%	$1.7B+49.6%	$1.1B-5.3%	$1.2B+13.0%	$1.0B
Cost of Revenue	$196.5M-19.9%	$245.3M-3.0%	$253.0M+16.0%	$218.1M+10.5%	$197.3M+10.7%	$178.3M
Gross Profit	$1.3B-2.5%	$1.3B-7.0%	$1.4B+57.8%	$893.7M-8.5%	$976.4M+13.5%	$860.4M
R&D Expenses	$324.0M+32.1%	$245.3M-9.4%	$270.8M-0.7%	$272.7M-6.3%	$290.9M-26.3%	$394.6M
SG&A Expenses	$701.5M+8.7%	$645.2M-6.5%	$689.8M+16.8%	$590.8M+7.5%	$549.6M+2.0%	$538.8M
Operating Income	$254.0M-39.6%	$420.6M+1.6%	$414.1M+6901.1%	-$6.1M-106.2%	$97.7M+186.9%	-$112.4M
Interest Expense	$12.3M-45.6%	$22.6M-2.0%	$23.0M+76.6%	$13.0M+16.2%	$11.2M+29.6%	$8.7M
Income Tax	$49.8M-30.5%	$71.6M+173.3%	-$97.6M-4924.0%	$2.0M-82.1%	$11.3M-20.9%	$14.3M
Net Income	$241.7M-34.2%	$367.1M+3.2%	$355.8M+324.8%	-$158.3M-228.4%	-$48.2M+56.5%	-$110.9M
EPS (Diluted)	$1.43-34.1%	$2.17+3.3%	$2.10+316.5%	$-0.97-234.5%	$-0.29+58.6%	$-0.70

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$392.9M+2.2%	$384.5M-2.4%	$394.2M+0.9%	$390.7M+27.5%	$306.5M-28.7%	$430.0M+13.7%	$378.1M-5.3%	$399.1M
Cost of Revenue	$61.6M+33.3%	$46.2M-10.4%	$51.6M+4.3%	$49.5M+0.5%	$49.2M-20.8%	$62.1M-1.6%	$63.1M+2.6%	$61.5M
Gross Profit	$331.3M-2.1%	$338.3M-1.2%	$342.6M+0.4%	$341.2M+32.6%	$257.3M-30.1%	$367.9M+16.8%	$315.0M-6.7%	$337.7M
R&D Expenses	$103.3M+11.1%	$93.0M+13.8%	$81.7M+5.6%	$77.4M+7.7%	$71.8M+23.5%	$58.2M-2.9%	$59.9M+0.4%	$59.6M
SG&A Expenses	$264.6M+41.3%	$187.2M+9.0%	$171.8M+0.5%	$170.8M-0.5%	$171.7M+16.8%	$147.0M-2.3%	$150.4M-10.5%	$168.1M
Operating Income	-$48.3M-183.1%	$58.1M-34.8%	$89.1M-4.2%	$93.0M+574.1%	$13.8M-91.5%	$162.7M+55.3%	$104.8M-4.7%	$109.9M
Interest Expense	$20.9M+70.2%	$12.3M	$0	$0	$0-100.0%	$4.6M-22.5%	$6.0M+0.8%	$6.0M
Income Tax	$4.6M-58.7%	$11.0M-38.6%	$18.0M+1.4%	$17.7M+486.5%	$3.0M-87.5%	$24.2M+38.5%	$17.4M-21.0%	$22.1M
Net Income	-$66.5M-234.6%	$49.4M-40.3%	$82.8M-5.0%	$87.1M+287.7%	$22.5M-84.7%	$146.5M+58.6%	$92.4M+1.1%	$91.4M
EPS (Diluted)	$-0.40	N/A	$0.49-5.8%	$0.52+300.0%	$0.13	N/A	$0.55+3.8%	$0.53

ALKS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.5B+21.0%	$2.1B-3.8%	$2.1B+8.8%	$2.0B-3.0%	$2.0B+3.8%	$1.9B
Current Assets	$1.9B+36.3%	$1.4B-4.7%	$1.5B+31.4%	$1.1B+6.4%	$1.1B-4.4%	$1.1B
Cash & Equivalents	$388.6M+33.5%	$291.1M-36.4%	$457.5M+56.4%	$292.5M-13.4%	$337.5M+23.7%	$273.0M
Inventory	$196.6M+7.5%	$182.9M-1.9%	$186.4M+2.7%	$181.4M+20.7%	$150.3M+19.6%	$125.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$83.0M0.0%	$83.0M0.0%	$83.0M0.0%	$83.0M-10.6%	$92.9M0.0%	$92.9M
Total Liabilities	$667.7M+13.1%	$590.6M-36.7%	$933.5M+1.4%	$920.2M+0.9%	$911.9M+3.3%	$882.7M
Current Liabilities	$543.4M+16.8%	$465.2M-10.6%	$520.2M+4.5%	$497.7M+5.6%	$471.3M+7.5%	$438.3M
Long-Term Debt	$0	N/A	$287.7M-0.9%	$290.3M-0.9%	$292.8M+7.6%	$272.1M
Total Equity	$1.8B+24.2%	$1.5B+21.8%	$1.2B+15.2%	$1.0B-6.2%	$1.1B+4.3%	$1.1B
Retained Earnings	-$734.8M+24.7%	-$976.5M+27.3%	-$1.3B+20.9%	-$1.7B-10.3%	-$1.5B-3.2%	-$1.5B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$4.3B+71.2%	$2.5B+6.8%	$2.3B+3.4%	$2.3B+8.2%	$2.1B+1.3%	$2.1B-4.6%	$2.2B-2.3%	$2.2B
Current Assets	$1.4B-29.6%	$1.9B+10.8%	$1.7B+6.5%	$1.6B+10.6%	$1.5B+4.5%	$1.4B-9.5%	$1.6B+1.4%	$1.5B
Cash & Equivalents	$351.6M-9.5%	$388.6M-37.0%	$616.4M+18.3%	$521.2M+30.4%	$399.8M+37.3%	$291.1M-26.5%	$396.3M-25.9%	$535.1M
Inventory	$336.7M+71.2%	$196.6M+2.9%	$191.0M-0.5%	$191.9M+4.6%	$183.4M+0.3%	$182.9M-4.3%	$191.1M-1.9%	$194.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$596.0M+617.9%	$83.0M	N/A	N/A	N/A	$83.0M0.0%	$83.0M0.0%	$83.0M
Total Liabilities	$2.5B+275.4%	$667.7M+12.0%	$596.1M-5.1%	$628.2M+10.1%	$570.4M-3.4%	$590.6M-31.6%	$863.2M-6.5%	$922.8M
Current Liabilities	$599.5M+10.3%	$543.4M+14.6%	$474.4M-6.2%	$506.0M+14.0%	$443.7M-4.6%	$465.2M+2.5%	$453.7M-12.0%	$515.5M
Long-Term Debt	$1.5B	$0	N/A	N/A	N/A	N/A	$285.8M-0.2%	$286.5M
Total Equity	$1.8B-3.7%	$1.8B+5.0%	$1.7B+6.7%	$1.6B+7.5%	$1.5B+3.2%	$1.5B+13.4%	$1.3B+0.6%	$1.3B
Retained Earnings	-$801.3M-9.0%	-$734.8M+6.3%	-$784.1M+9.5%	-$866.9M+9.1%	-$954.0M+2.3%	-$976.5M+13.0%	-$1.1B+7.6%	-$1.2B

ALKS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$520.8M+18.6%	$439.1M+9.4%	$401.4M+1807.2%	$21.0M-79.3%	$101.7M+22.8%	$82.8M
Capital Expenditures	$40.4M+20.7%	$33.5M-30.3%	$48.0M+25.6%	$38.3M+36.5%	$28.0M-33.6%	$42.2M
Free Cash Flow	$480.3M+18.4%	$405.6M+14.8%	$353.3M+2152.8%	-$17.2M-123.4%	$73.7M+81.4%	$40.6M
Investing Cash Flow	$295.5M+365.5%	-$111.3M-308.6%	$53.4M+182.7%	-$64.5M+2.5%	-$66.2M-476.6%	-$11.5M
Financing Cash Flow	$12.4M+102.5%	-$494.1M-70.6%	-$289.7M-18306.2%	-$1.6M-105.4%	$29.1M+1439.1%	-$2.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$200.3M	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$165.7M-197.5%	$170.1M+67.3%	$101.7M-32.3%	$150.2M+52.0%	$98.8M-48.1%	$190.4M+133.4%	$81.6M-44.1%	$146.0M
Capital Expenditures	$4.1M+20550.0%	-$20K-100.1%	$17.3M+33.0%	$13.0M+28.7%	$10.1M+3.4%	$9.8M+18.3%	$8.3M+16.1%	$7.1M
Free Cash Flow	-$169.8M-199.9%	$170.0M+101.6%	$84.4M-38.5%	$137.2M+54.7%	$88.7M-50.9%	$180.6M+146.3%	$73.3M-47.2%	$138.9M
Investing Cash Flow	-$2.1B-744.3%	$322.3M+4884.7%	-$6.7M+76.9%	-$29.2M-421.0%	$9.1M+165.6%	-$13.9M+87.3%	-$109.3M-310.9%	$51.9M
Financing Cash Flow	$1.5B+13412.8%	$10.9M+3364.1%	$315K-22.2%	$405K-45.8%	$747K+100.3%	-$281.7M-153.5%	-$111.1M-33.1%	-$83.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$27.7M	N/A	N/A	N/A	N/A	$1K-100.0%	$115.6M	N/A

ALKS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	86.7%+2.4pp	84.3%-0.5pp	84.8%+4.4pp	80.4%-2.8pp	83.2%+0.4pp	82.8%
Operating Margin	17.2%-9.8pp	27.0%+2.1pp	24.9%+25.4pp	-0.5%-8.9pp	8.3%+19.1pp	-10.8%
Net Margin	16.4%-7.2pp	23.6%+2.2pp	21.4%+35.6pp	-14.2%-10.1pp	-4.1%+6.6pp	-10.7%
Return on Equity	13.3%-11.8pp	25.1%-4.5pp	29.6%+44.8pp	-15.2%-10.8pp	-4.3%+6.1pp	-10.4%
Return on Assets	9.7%-8.1pp	17.9%+1.2pp	16.7%+24.7pp	-8.1%-5.7pp	-2.4%+3.3pp	-5.7%
Current Ratio	3.55+0.5	3.04+0.2	2.86+0.6	2.27+0.0	2.25-0.3	2.54
Debt-to-Equity	0.00-0.4	0.40+0.2	0.24-0.0	0.28+0.0	0.260.0	0.26
FCF Margin	32.6%+6.5pp	26.0%+4.8pp	21.2%+22.8pp	-1.6%-7.8pp	6.3%+2.4pp	3.9%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	84.3%-3.6pp	88.0%+1.1pp	86.9%-0.4pp	87.3%+3.4pp	84.0%-1.6pp	85.5%+2.2pp	83.3%-1.3pp	84.6%
Operating Margin	-12.3%-27.4pp	15.1%-7.5pp	22.6%-1.2pp	23.8%+19.3pp	4.5%-33.3pp	37.8%+10.1pp	27.7%+0.2pp	27.5%
Net Margin	-16.9%-29.8pp	12.8%-8.2pp	21.0%-1.3pp	22.3%+15.0pp	7.3%-26.7pp	34.1%+9.7pp	24.4%+1.5pp	22.9%
Return on Equity	-3.8%-6.5pp	2.7%-2.1pp	4.8%-0.6pp	5.4%+3.9pp	1.5%-8.5pp	10.0%+2.9pp	7.1%+0.0pp	7.1%
Return on Assets	-1.6%-3.6pp	2.0%-1.6pp	3.5%-0.3pp	3.9%+2.8pp	1.1%-6.0pp	7.1%+2.8pp	4.3%+0.2pp	4.1%
Current Ratio	2.27-1.3	3.55-0.1	3.67+0.4	3.23-0.1	3.33+0.3	3.04-0.4	3.45+0.5	2.99
Debt-to-Equity	0.85+0.8	0.00-0.3	0.34-0.0	0.390.0	0.38-0.0	0.40+0.2	0.220.0	0.22
FCF Margin	-43.2%-87.4pp	44.2%+22.8pp	21.4%-13.7pp	35.1%+6.2pp	28.9%-13.1pp	42.0%+22.6pp	19.4%-15.4pp	34.8%

Similar Companies

Lantheus Holding LNTH

$6.7B

Indivior Pharmaceuticals Inc. INDV

$4.4B

Amneal Pharmaceuticals Inc AMRX

$4.0B

Hutchmed (China) Limited HCM

$2.1B

Prestige Consmr Healthcare Inc PBH

$2.3B

Frequently Asked Questions

What is Alkermes Plc's annual revenue?

Alkermes Plc (ALKS) reported $1.5B in total revenue for fiscal year 2025. This represents a -5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Alkermes Plc's revenue growing?

Alkermes Plc (ALKS) revenue declined by 5.2% year-over-year, from $1.6B to $1.5B in fiscal year 2025.

Is Alkermes Plc profitable?

Yes, Alkermes Plc (ALKS) reported a net income of $241.7M in fiscal year 2025, with a net profit margin of 16.4%.

What is Alkermes Plc's EBITDA?

Alkermes Plc (ALKS) had EBITDA of $281.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Alkermes Plc have?

As of fiscal year 2025, Alkermes Plc (ALKS) had $388.6M in cash and equivalents against $0 in long-term debt.

What is Alkermes Plc's gross margin?

Alkermes Plc (ALKS) had a gross margin of 86.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Alkermes Plc's operating margin?

Alkermes Plc (ALKS) had an operating margin of 17.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Alkermes Plc's net profit margin?

Alkermes Plc (ALKS) had a net profit margin of 16.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Alkermes Plc's return on equity (ROE)?

Alkermes Plc (ALKS) has a return on equity of 13.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Alkermes Plc's free cash flow?

Alkermes Plc (ALKS) generated $480.3M in free cash flow during fiscal year 2025. This represents a 18.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Alkermes Plc's operating cash flow?

Alkermes Plc (ALKS) generated $520.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Alkermes Plc's total assets?

Alkermes Plc (ALKS) had $2.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Alkermes Plc's capital expenditures?

Alkermes Plc (ALKS) invested $40.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Alkermes Plc spend on research and development?

Alkermes Plc (ALKS) invested $324.0M in research and development during fiscal year 2025.

How many shares does Alkermes Plc have outstanding?

Alkermes Plc (ALKS) had 166M shares outstanding as of fiscal year 2025.

What is Alkermes Plc's current ratio?

Alkermes Plc (ALKS) had a current ratio of 3.55 as of fiscal year 2025, which is generally considered healthy.

What is Alkermes Plc's debt-to-equity ratio?

Alkermes Plc (ALKS) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Alkermes Plc's return on assets (ROA)?

Alkermes Plc (ALKS) had a return on assets of 9.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Alkermes Plc's Altman Z-Score?

Alkermes Plc (ALKS) has an Altman Z-Score of 6.72, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Alkermes Plc's Piotroski F-Score?

Alkermes Plc (ALKS) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Alkermes Plc's earnings high quality?

Alkermes Plc (ALKS) has an earnings quality ratio of 2.15x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Alkermes Plc cover its interest payments?

Alkermes Plc (ALKS) has an interest coverage ratio of 20.7x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Alkermes Plc?

Alkermes Plc (ALKS) scores 69 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.